Abstract

Pharmacologic innovation in assisted reproduction has progressed more slowly than advances in embryology and laboratory technologies, leaving modern in vitro fertilisation protocols largely dependent on hormonal approaches established decades ago.

This article examines the evolution of fertility therapeutics from early urinary-derived gonadotropins to contemporary recombinant biologics, highlighting how improvements in purification and manufacturing have enhanced product consistency without fundamentally altering underlying treatment paradigms. It explores the unique scientific and operational challenges of fertility drug development, including heterogeneous patient populations, multifactorial treatment outcomes, and the temporal disconnect between pharmacologic intervention and clinically meaningful endpoints, such as pregnancy and live birth. Regulatory expectations further complicate development, with varying global standards and an increasing emphasis on demonstrating clinically relevant outcomes while ensuring maternal, fetal and offspring safety. Manufacturing complexity, particularly for glycoprotein hormones, adds another layer of difficulty, alongside device integration for patient-administered therapies.

Despite these challenges, emerging opportunities exist across the reproductive pathway, from ovarian stimulation to pregnancy maintenance and fertility preservation. Advances in reproductive biology, biomarker-driven approaches and stage-specific interventions offer the potential to expand beyond traditional hormonal strategies. Future progress will depend on aligning biological innovation with appropriate clinical endpoints, regulatory frameworks and patient-centred outcomes to deliver meaningful improvements in reproductive care.